<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03216967</url>
  </required_header>
  <id_info>
    <org_study_id>6646</org_study_id>
    <nct_id>NCT03216967</nct_id>
  </id_info>
  <brief_title>Multicenter Randomized Two-arms Study Evaluating the BK Viral Clearance in Kidney Transplant Recipients With BK Viremia.</brief_title>
  <acronym>BK EVER</acronym>
  <official_title>Multicenter Randomized Two-arms Study Evaluating the BK Viral Clearance in Kidney Transplant Recipients With BK Viremia After Reduction of Immunosuppression Alone vs. Reduction of Immunosuppression and Replacement of Mycophenolate Mofetil by Everolimus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      BK virus nephropathy (BKVN), a consequence of the strong immunosuppressive therapy given&#xD;
      after kidney transplantation, represents a growing problem in the kidney transplant (KT)&#xD;
      setting. In recent cohorts, BKVN concerns up to 10% of kidney transplant recipients and early&#xD;
      signs of BK virus (BKV) infection as development of asymptomatic viruria and viremia are even&#xD;
      much more frequent (40% and 20% of patients, respectively). In this context, finding&#xD;
      strategies to prevent BKV infection or treat patients before the occurrence of BKV&#xD;
      nephropathy is challenging. For several years, detection of BKV replication by real-time PCR&#xD;
      in urine and/or blood of kidney transplant recipients at early stages of infection allowed&#xD;
      adaptation of their therapy. As BKV reactivates essentially in patients with&#xD;
      over-immunosuppression, the first step of the treatment is the reduction of&#xD;
      immunosuppression. However, reducing immunosuppression (IS) can lead to acute rejection and&#xD;
      allograft loss. Other treatments have been proposed (cidofovir, quinolones) but their&#xD;
      toxicity profile or their lack of clinical efficacy are now demonstrated. Hence, an efficient&#xD;
      and safe strategy against uncontrolled BKV replication is urgently needed. MTor-inhibitors&#xD;
      are well known immunosuppressive drugs used in organ transplantation to prevent&#xD;
      graft-rejection. They have furthermore anti-viral effects that can be beneficial for&#xD;
      prevention of viral infections after transplantation. Recent evidence that inhibition of mTor&#xD;
      pathway had an impact on BK infected cells provides additional insight into the observed&#xD;
      benefits associated with these drugs. The aim of our study is to evaluate the effect of the&#xD;
      mTor inhibitor everolimus on the prevention of severe BKV infection (BKV nephropathy or loss&#xD;
      of the allograft) after kidney transplantation compared to the reduction of immunosuppression&#xD;
      alone in kidney recipients with BK viremia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The main objective of our study is to evaluate the proportion of patients with BKV clearance 6 months after introduction of everolimus in kidney recipients who develop BKV viremia compared to patients managed with IS reduction alone</measure>
    <time_frame>6 months after randomization</time_frame>
    <description>The primary end point is the proportion of patients with clearance of BK viremia assessed by blood PCR and functional graft 6 months after modification of immunosuppressive therapy</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>BK Virus Nephropathy After Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>IS lowering alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50% decrease of the dose of mycophenolic acid at M1 (target AUC 20 mg.h/L)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Everolimus + IS lowering</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stop mycophenolate acid (Cellcept or myfortic) Introduction of everolimus : 2 x 0.75 mg/d per os in patiens treated by ciclosporine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>everolimus</intervention_name>
    <description>Patients with viremia above 3 log of copies/ml will be randomized (ratio 1:1) into either of 2 groups Group 1 : control group : immunosuppression lowering or Group 2 : experimental group : immunosuppression lowering and replacement of mycophenolate acid by everolimus Evolution of BKV viremia and allograft function will be assessed during 2 years after randomization</description>
    <arm_group_label>Everolimus + IS lowering</arm_group_label>
    <arm_group_label>IS lowering alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients&#xD;
&#xD;
          -  Kidney transplant recipients&#xD;
&#xD;
          -  Patients treated by a calcineurin inhibitor and mycophenolic acid&#xD;
&#xD;
          -  Viremia &gt;= 3 log UI/ml&#xD;
&#xD;
          -  Patients who have given written informed consent&#xD;
&#xD;
          -  Negative pregnancy test (blood β-HCG dosage)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known proved BKV nephropathy&#xD;
&#xD;
          -  Hypersensitivity to everolimus, sirolimus or excipient&#xD;
&#xD;
          -  Concomitant treatment by leflunomide, cidofovir, sirolimus, Millepertuis (Hypericum&#xD;
             Perforatum)&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Women of child bearing potential unless they are using a birth control method&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU - Hôpital Sud</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU - Hôpital de la Cavale Blanche</name>
      <address>
        <city>Bois-guillaume</city>
        <zip>76230</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU - Hôpital de la Cavale Blanche</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hôpital Gabriel Montpied</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU - Hôpital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP - Hôpital Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers - Hôpital Jean Bernard</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU - Hôpital Maison Blanche</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rennes - Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Les Hôpitaux Universitaires</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU - Hôpital Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 4, 2017</study_first_submitted>
  <study_first_submitted_qc>July 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2017</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Viremia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

